{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:11:57Z","timestamp":1792840317024,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10439-y","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T04:19:29Z","timestamp":1736137169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Use of isavuconazole in mucormycosis: a systematic review"],"prefix":"10.1186","volume":"25","author":[{"given":"Shobha Sanjeewani","family":"Gunathilaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshani Kaumada","family":"Keragala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasun Madhumal","family":"Gunathilaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujanthi","family":"Wickramage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachithra Ravindi","family":"Bandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indika Sanjeewa","family":"Senevirathne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asela Sampath","family":"Jayaweera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"issue":"3","key":"10439_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2217\/fmb-2022-0141","volume":"18","author":"I Gupta","year":"2023","unstructured":"Gupta I, Baranwal P, Singh G, Gupta V. Mucormycosis, past and present: a comprehensive review. Future Microbiol. 2023;18(3):217\u201334.","journal-title":"Future Microbiol"},{"key":"10439_CR2","doi-asserted-by":"publisher","first-page":"111643","DOI":"10.1016\/j.envres.2021.111643","volume":"201","author":"I Mahalaxmi","year":"2021","unstructured":"Mahalaxmi I, Jayaramayya K, Venkatesan D, Subramaniam MD, Renu K, Vijayakumar P, et al. Mucormycosis: an opportunistic pathogen during COVID-19. Environ Res. 2021;201:111643.","journal-title":"Environ Res"},{"issue":"12","key":"10439_CR3","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","volume":"19","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405\u201321.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10439_CR4","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1086\/599105","volume":"48","author":"B Spellberg","year":"2009","unstructured":"Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr., Ibrahim AS. Recent advances in the management of mucormycosis: from bench to Bedside. Clin Infect Dis. 2009;48(12):1743\u201351.","journal-title":"Clin Infect Dis"},{"key":"10439_CR5","doi-asserted-by":"crossref","unstructured":"Smith C, Lee SC. Current treatments against mucormycosis and future directions. Chowdhary A, editor. PLOS Pathog. 2022;18(10):e1010858.","DOI":"10.1371\/journal.ppat.1010858"},{"key":"10439_CR6","unstructured":"PROSPERO- International prospective register of systematic reviews. Available from: https:\/\/www.crd.york.ac.uk\/prospero\/"},{"key":"10439_CR7","unstructured":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Available from: http:\/\/www.prisma-statement.org\/"},{"key":"10439_CR8","unstructured":"Z AE, I I FHH. Rayyan: a systematic reviews web app for exploring and filtering searches for eligible studies for Cochrane Reviews. Abstracts of the 22nd Cochrane Colloquium. Wiley; 2014. 9."},{"key":"10439_CR9","doi-asserted-by":"crossref","unstructured":"Egger M, Bellmann R, Krause R, Boyer J, Jak\u0161i\u0107 D, Hoenigl M. Salvage Treatment for Invasive Aspergillosis and Mucormycosis: Challenges, Recommendations and Future Considerations. Infect Drug Resist. 2023; 16:2167\u201378. Available from: https:\/\/www.dovepress.com\/salvage-treatment-for-invasive-aspergillosis-and-mucormycosis-challeng-peer-reviewed-fulltext-article-IDR","DOI":"10.2147\/IDR.S372546"},{"issue":"2","key":"10439_CR10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/myc.13412","volume":"65","author":"GR Thompson 3rd","year":"2022","unstructured":"Thompson GR 3rd, Garcia-Diaz J, Miceli MH, Nguyen MH, Ostrosky-Zeichner L, Young J-AH, et al. Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): a multicentre, non-interventional registry study. Mycoses. 2022;65(2):186\u201398.","journal-title":"Mycoses"},{"issue":"10273","key":"10439_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","volume":"397","author":"JA Maertens","year":"2021","unstructured":"Maertens JA, Rahav G, Lee D-G, Ponce-de-Le\u00f3n A, Ram\u00edrez S\u00e1nchez IC, Klimko N, et al. Posaconazole versus Voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397(10273):499\u2013509.","journal-title":"Lancet"},{"key":"10439_CR12","first-page":"21","volume":"8","author":"FM Marty","year":"2014","unstructured":"Marty FM, Perfect JR, Cornely OA, Mullane KM, Rahav G, Lee M, et al. An open-label phase 3 study of isavuconazole (VITAL): focus on mucormycosis. Risk. 2014;8:21\u20136.","journal-title":"Risk"},{"key":"10439_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijid.2022.04.009","volume":"120","author":"R Soman","year":"2022","unstructured":"Soman R, Chakraborty S, Joe G. Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series. Int J Infect Dis [Internet]. 2022;120:177\u20138.","journal-title":"Int J Infect Dis [Internet]"},{"issue":"2","key":"10439_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.amjoto.2015.12.003","volume":"37","author":"Y Ahmed","year":"2016","unstructured":"Ahmed Y, Delaney S, Markarian A. Successful isavuconazole therapy in a patient with acute invasive fungal rhinosinusitis and acquired immune deficiency syndrome. Am J Otolaryngol. 2016;37(2):152\u20135.","journal-title":"Am J Otolaryngol"},{"key":"10439_CR15","doi-asserted-by":"crossref","unstructured":"Brigmon B MM, Ochoa, Brust K. Successful long-term therapy of mucormycosis with isavuconazole. Proc (Baylor Univ Med Center). 2021;34:703\u20134.","DOI":"10.1080\/08998280.2021.1935138"},{"key":"10439_CR16","doi-asserted-by":"crossref","unstructured":"Tran D, Schmit B. An aggressive case of Mucormycosis. Cureus. 2020;12. e9610.","DOI":"10.7759\/cureus.9610"},{"key":"10439_CR17","doi-asserted-by":"crossref","unstructured":"Ilharco M, Pereira CM, Moreira L, Proen\u00e7a AL, do Carmo Fevereiro M, Lampreia F et al. Rhinoorbital mucormycosis in the immunocompetent: Experience with Isavuconazole. Vol. 18, IDCases. 2019. e00591.","DOI":"10.1016\/j.idcr.2019.e00591"},{"issue":"4","key":"10439_CR18","doi-asserted-by":"publisher","first-page":"101046","DOI":"10.1016\/j.mycmed.2020.101046","volume":"30","author":"X Dur\u00e0-Miralles","year":"2020","unstructured":"Dur\u00e0-Miralles X, Escol\u00e0-Verg\u00e9 L, Moreno D, Mart\u00ednez-Ricarte F, Lung M, Fern\u00e1ndez-Hidalgo N, et al. Isolated cerebral mucormycosis associated with intravenous drug use. J Mycol Med. 2020;30(4):101046.","journal-title":"J Mycol Med"},{"key":"10439_CR19","first-page":"e2547","volume":"10","author":"M Shafiq","year":"2018","unstructured":"Shafiq M, Ali Z, Ukani R, Brewer J. Isavuconazole: a promising salvage therapy for Invasive Mucormycosis. Cureus. 2018;10:e2547.","journal-title":"Cureus"},{"issue":"1","key":"10439_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11046-018-0281-6","volume":"184","author":"BK Thielen","year":"2019","unstructured":"Thielen BK, Barnes AMT, Sabin AP, Huebner B, Nelson S, Wesenberg E, et al. Widespread lichtheimia infection in a patient with extensive Burns: opportunities for Novel Antifungal agents. Mycopathologia. 2019;184(1):121\u20138.","journal-title":"Mycopathologia"},{"key":"10439_CR21","doi-asserted-by":"crossref","unstructured":"Gani I, Doroodchi A, Falkenstrom K, Berry H, Lee W, Mulloy L et al. Gastric Mucormycosis in a Renal Transplant Patient Treated with Isavuconazole Monotherapy. Vol. 2019, Case reports in transplantation. 2019. p. 9839780.","DOI":"10.1155\/2019\/9839780"},{"key":"10439_CR22","doi-asserted-by":"crossref","unstructured":"Beaver R, Garza B, Vallabhaneni H, Cahuayme-Zuniga L, Midturi J, LaDow T. Use of topical amphotericin in a case of refractory sino-orbital angioinvasive mucormycosis. 33, Medical mycology case reports. 2021. pp. 21\u20135.","DOI":"10.1016\/j.mmcr.2021.06.003"},{"key":"10439_CR23","first-page":"2537186","volume":"2022","author":"L Ponce-Rosas","year":"2022","unstructured":"Ponce-Rosas L, Gonzales-Zamora J, Diaz-Reyes N, Alarco-Cadillo O, Alave-Rosas J. Rhino-Orbital-Cerebral Mucormycosis in a Post-COVID-19 patient from Peru. Case Rep Infect Dis. 2022;2022:2537186.","journal-title":"Case Rep Infect Dis"},{"key":"10439_CR24","doi-asserted-by":"crossref","unstructured":"Kou C, Rendo M, Kline D, Bishop B, Yun HC. An unusual cause of bowel obstruction: Rhizopus Arrhizus diverticulitis. 25, Medical mycology case reports. 2019. pp. 15\u20138.","DOI":"10.1016\/j.mmcr.2019.06.004"},{"issue":"3","key":"10439_CR25","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1128\/JCM.03176-13","volume":"52","author":"D Peixoto","year":"2014","unstructured":"Peixoto D, Gagne LS, Hammond SP, Gilmore ET, Joyce AC, Soiffer RJ, et al. Isavuconazole treatment of a patient with disseminated mucormycosis. J Clin Microbiol. 2014;52(3):1016\u20139.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10439_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s15010-013-0552-6","volume":"42","author":"J Ervens","year":"2014","unstructured":"Ervens J, Ghannoum M, Graf B, Schwartz S. Successful isavuconazole salvage therapy in a patient with invasive mucormycosis. Infection. 2014;42(2):429\u201332.","journal-title":"Infection"},{"key":"10439_CR27","first-page":"e24932","volume":"14","author":"M Duarte","year":"2022","unstructured":"Duarte M, Tiago V, Camble A, Sousa R, Aldomiro F. Pulmonary mucormycosis in a poorly controlled Diabetic Patient. Cureus. 2022;14:e24932.","journal-title":"Cureus"},{"key":"10439_CR28","doi-asserted-by":"crossref","unstructured":"Sanku K, Youssef D. Coexistence of Mucormycosis and Granulomatosis With Polyangiitis: A Diagnostic and Therapeutic Challenge. Vol. 14, Cureus. 2022. p. e25124.","DOI":"10.7759\/cureus.25124"},{"key":"10439_CR29","doi-asserted-by":"crossref","unstructured":"Hoang K, Abdo T, Reinersman JM, Lu R, Higuita NIA. A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient. 29, Medical mycology case reports. 2020. pp. 22\u20134.","DOI":"10.1016\/j.mmcr.2020.05.008"},{"key":"10439_CR30","doi-asserted-by":"crossref","unstructured":"Huggins J, Al Jurdi A, Gupta R. Breaking the mold: a case of pulmonary mucormycosis treated with isavuconazole. 23, Medical mycology case reports. 2019. pp. 34\u20136.","DOI":"10.1016\/j.mmcr.2018.11.004"},{"key":"10439_CR31","doi-asserted-by":"crossref","unstructured":"Izaguirre-Anariba DE, Chee F, Thet Z, Lanza J. An Interesting Case of a 57-Year-Old Male with an Upper Gastrointestinal Bleeding and Obstructive Uropathy with Bilateral Hydronephrosis Diagnosed with Systemic Mucormycosis. Vol. 2018, Case reports in infectious diseases. 2018. p. 6283701.","DOI":"10.1155\/2018\/6283701"},{"key":"10439_CR32","doi-asserted-by":"crossref","unstructured":"Zuglian G, Ripamonti D, Tebaldi A, Rizzi M. Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: a case report. 26, Medical mycology case reports. 2019. pp. 42\u20133.","DOI":"10.1016\/j.mmcr.2019.10.002"},{"key":"10439_CR33","doi-asserted-by":"crossref","unstructured":"Hammoudi DAS, Morar MM, Garbuzov A, Urias D, Katira KM. Lower extremity salvage in a Diabetic patient with cutaneous mucormycosis and COVID-19 after Open Patella fracture. Ochsner J. 2022;22:163\u20138.","DOI":"10.31486\/toj.21.0099"},{"key":"10439_CR34","doi-asserted-by":"crossref","unstructured":"Martin MS, Smith AA, Lobo M, Paramesh AS. Successful Treatment of Recurrent Pulmonary Mucormycosis in a Renal Transplant Patient: A Case Report and Literature Review. Vol. 2017, Case reports in transplantation. 2017. p. 1925070.","DOI":"10.1155\/2017\/1925070"},{"issue":"8","key":"10439_CR35","first-page":"863","volume":"26","author":"A Ferdjallah","year":"2021","unstructured":"Ferdjallah A, Nelson KM, Meyer K, Jennissen CA, Ebens CL. Isavuconazonium Sulfate Use in Multi-modal Management of Invasive Mucormycosis in Four Pediatric Allogeneic hematopoietic cell transplant patients. J Pediatr Pharmacol Ther JPPT off J PPAG. 2021;26(8):863\u20137.","journal-title":"J Pediatr Pharmacol Ther JPPT off J PPAG"},{"key":"10439_CR36","doi-asserted-by":"crossref","unstructured":"Vu CA, Rana MM, Jacobs SE, Saunders-Hao P. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: a single\u2010center experience. Transpl Infect Dis [Internet]. 2021;23(2).","DOI":"10.1111\/tid.13469"},{"issue":"8","key":"10439_CR37","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/INF.0000000000002671","volume":"39","author":"L Ashkenazi-Hoffnung","year":"2020","unstructured":"Ashkenazi-Hoffnung L, Bilavsky E, Levy I, Grisaru G, Sadot E, Ben-Ami R, et al. Isavuconazole as successful salvage therapy for Mucormycosis in Pediatric patients. Pediatr Infect Dis J. 2020;39(8):718\u201324.","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"10439_CR38","doi-asserted-by":"publisher","first-page":"e27281","DOI":"10.1002\/pbc.27281","volume":"65","author":"AA Barg","year":"2018","unstructured":"Barg AA, Malkiel S, Bartuv M, Greenberg G, Toren A, Keller N. Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients. Pediatr Blood Cancer. 2018;65(10):e27281.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10439_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11046-018-0287-0","volume":"184","author":"A Pomorska","year":"2019","unstructured":"Pomorska A, Malecka A, Jaworski R, Radon-Proskura J, Hare RK, Nielsen HV, et al. Isavuconazole in a successful combination treatment of disseminated mucormycosis in a child with Acute Lymphoblastic Leukaemia and generalized haemochromatosis: a Case Report and Review of the literature. Mycopathologia. 2019;184(1):81\u20138.","journal-title":"Mycopathologia"},{"issue":"1","key":"10439_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40360-018-0273-7","volume":"19","author":"M Cornu","year":"2018","unstructured":"Cornu M, Bruno B, Loridant S, Navarin P, Fran\u00e7ois N, Lanternier F, et al. Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report. BMC Pharmacol Toxicol. 2018;19(1):81.","journal-title":"BMC Pharmacol Toxicol"},{"key":"10439_CR41","doi-asserted-by":"publisher","first-page":"844880","DOI":"10.3389\/fmed.2022.844880","volume":"9","author":"P Sosnowska-Sienkiewicz","year":"2022","unstructured":"Sosnowska-Sienkiewicz P, B\u0142aszczyk K, Kubisiak-Rzepczyk H, Ma\u0144kowski P, Januszkiewicz-Lewandowska D. How to treat a child with a concurrent diagnosis of leukemia and generalized mucormycosis? Case Report. Front Med. 2022;9:844880.","journal-title":"Front Med"},{"issue":"7","key":"10439_CR42","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","volume":"16","author":"FM Marty","year":"2016","unstructured":"Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828\u201337.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10439_CR43","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/antibiotics10050487","volume":"10","author":"M Risum","year":"2021","unstructured":"Risum M, Vestergaard M-B, Weinreich UM, Helleberg M, Vissing NH, J\u00f8rgensen R. Therapeutic drug monitoring of Isavuconazole: serum concentration variability and success rates for reaching target in comparison with Voriconazole. Antibiot [Internet]. 2021;10(5):487.","journal-title":"Antibiot [Internet]"},{"key":"10439_CR44","doi-asserted-by":"crossref","unstructured":"Sigera LSM, Denning DW. A systematic review of the therapeutic outcome of Mucormycosis. Open Forum Infect Dis [Internet]. 2024;11(1).","DOI":"10.1093\/ofid\/ofad704"},{"issue":"2","key":"10439_CR45","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/jof9020166","volume":"9","author":"MV Batista","year":"2023","unstructured":"Batista MV, Ussetti MP, Jiang Y, Neofytos D, Cortez AC, Feriani D, et al. Comparing the real-world use of Isavuconazole to other anti-fungal therapy for invasive fungal infections in patients with and without underlying disparities: a Multi-center Retrospective Study. J Fungi. 2023;9(2):166.","journal-title":"J Fungi"},{"issue":"10020","key":"10439_CR46","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus Voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet [Internet]. 2016;387(10020):760\u20139.","journal-title":"Lancet [Internet]"},{"issue":"7","key":"10439_CR47","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3111\/13696998.2016.1164175","volume":"19","author":"D Horn","year":"2016","unstructured":"Horn D, Goff D, Khandelwal N, Spalding J, Azie N, Shi F, et al. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial. J Med Econ. 2016;19(7):728\u201334.","journal-title":"J Med Econ"},{"issue":"4","key":"10439_CR48","doi-asserted-by":"publisher","first-page":"260","DOI":"10.5005\/jp-journals-10071-24443","volume":"27","author":"S Saseedharan","year":"2023","unstructured":"Saseedharan S, Prayag PS, Soman RN, Panchakshari SP, Ajapuje PS, Mahale NP, et al. Therapeutic drug monitoring of Isavuconazole: lessons Learnt from a real-life setting in a Tertiary Care Center in India. Indian J Crit Care Med [Internet]. 2023;27(4):260\u20134.","journal-title":"Indian J Crit Care Med [Internet]"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10439-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10439-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10439-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:01:43Z","timestamp":1736182903000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10439-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10439"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10439-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}